AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Related Articles
Anumana’s AI-Driven Low Ejection Fraction ECG-AI Technology Recognized in CMS 2025 OPPS Final Rule, Expanding Access to Advanced Cardiovascular Care
Company’s ECG-AI algorithm enables earlier heart failure detectionNovember 05, 2024
Anumana Advances AI-Driven Cardiovascular Science with Late-Breaking Heart Failure Study and Multiple Abstracts at AHA 2025
Simultaneous publication in Journal of the American College of Cardiology demonstrates impact of ECG-AI on heart failure risk assessment. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in AI-powered cardiovascular diagnostics, today announced…November 20, 2025
Anumana Appoints Maulik Nanavaty as CEO
Anumana Appoints Maulik Nanavaty as CEOCAMBRIDGE, Mass. – October 19, 2023 – Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, today announced that Maulik Nanavaty…October 19, 2023
Anumana wins FDA clearance for ECG-AI algorithm
Mass Device: Anumana announced that it received FDA 510(k) clearance for its AI-powered ECG-AI LEF medical device.October 03, 2023